Scarica l'app Stockscreener
47.19
2.34%
1.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$46.11
Aprire:
$46.49
Volume 24 ore:
4.23M
Relative Volume:
0.83
Capitalizzazione di mercato:
$95.79B
Reddito:
$42.06B
Utile/perdita netta:
$7.96B
Rapporto P/E:
13.46
EPS:
3.5062
Flusso di cassa netto:
$5.64B
1 W Prestazione:
+0.02%
1M Prestazione:
+7.40%
6M Prestazione:
+22.44%
1 anno Prestazione:
+40.03%
Intervallo 1D:
$46.47
$47.31
Intervallo di 1 settimana:
$45.80
$47.98
Portata 52W:
$31.71
$48.69
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GSK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
47.19 | 93.13B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
1,059.70 | 933.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.90 | 489.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
236.28 | 405.53B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
127.31 | 238.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.76 | 235.72B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-03 | Downgrade | Berenberg | Buy → Hold |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
JPMorgan Lowers GSK Price Target, Maintains Underweight Rating - Finviz
Alector Stock Plummets 63% in a Month: Here's What You Need to Know - Finviz
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
GSK PLC Share Price: What to Know Before the London Market Opens on 17 November 2025 - ts2.tech
The Best Healthcare Stock to Hold in Uncertain Times - Finviz
Looking Into GSK PLC's Recent Short Interest - Sahm
3 Dividend Stocks for November 2025 - Morningstar
10 Best Value Stocks to Buy for the Long Term - Morningstar
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Analysts - MarketBeat
Arkadios Wealth Advisors Acquires 6,734 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR Plans Quarterly Dividend of $0.42 (NYSE:GSK) - MarketBeat
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View - TradingView
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026 - Sahm
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
Whittier Trust Co. Sells 5,805 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
GSK plc Sponsored ADR (GSK) Stock Price Prediction for 2025, 2026, 2030-2040 - Traders Union
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - Sahm
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK) - The Globe and Mail
GSK PLC Sponsored ADR $GSK Shares Acquired by Ethic Inc. - MarketBeat
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Sahm
Stanley Laman Group Ltd. Decreases Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment - Sahm
The Best Healthcare Stocks to Buy - Morningstar
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm
Rep. Val T. Hoyle Sells GSK PLC Sponsored ADR (NYSE:GSK) Stock - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - The Globe and Mail
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why GSK (GSK) is a Top Value Stock for the Long-Term - sharewise.com
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
Park Place Capital Corp Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Bought by Farther Finance Advisors LLC - Defense World
GlaxoSmithKline (GSK) Gets a Hold from Barclays - The Globe and Mail
Sound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield Group - MarketBeat
The 10 Best Companies to Invest in Now - Morningstar
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
TD Private Client Wealth LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):